Geoff Nichol, M.B. Ch.B., MBA, FRACP, joined BioMarin in 2016 and currently serves as Chief Medical Officer and Senior Vice President, Global Clinical Development. At BioMarin, Dr. Nichol has managed an active portfolio of clinical development programs for our commercial products, as well as development of our investigational therapies for the treatment of achondroplasia and hemophilia A.
From 2011 to 2016, Dr. Nichol served as Executive Vice President, R&D at Sangamo BioSciences, where he managed the preclinical development of several genome editing IND candidates, both in vivo and ex vivo in T cells and hematopoietic stem cells, as well as an AAV cDNA FVIII gene therapy for hemophilia A, all now in active clinical development. From 2002 to 2009, Dr. Nichol was Senior Vice President of Development at Medarex, where he was responsible for the clinical development of the breakthrough cancer immunotherapy checkpoint inhibitors Yervoy (Phase 1 through Phase 3) and Opdivo (Phase 1), culminating in the acquisition of Medarex by Bristol Myers Squibb and the award of a Nobel Prize in Physiology or Medicine to the scientific originators. As a Vice President at Novartis from 1996 to 2002, he successively managed a pulmonary/women’s health clinical development therapeutic area, U.S. Medical Affairs and Global Project and Portfolio Management, with leadership roles in the Foradil and Xolair development programs. Prior to Novartis, Dr. Nichol worked at SmithKline Beecham on the approval of Augmentin BID in 1996 for adults and children for all indications.
Dr. Nichol received a B.Med.Sc., M.B. Ch.B. degree from Otago University Medical School and an MBA from the Warwick University Business School. He currently serves on the Millendo Therapeutics Board of Directors.